keyword
MENU ▼
Read by QxMD icon Read
search

Metabolic syndrome antipsychotic

keyword
https://www.readbyqxmd.com/read/28719155/antipsychotic-treatment-is-associated-with-inflammatory-and-metabolic-biomarkers-alterations-among-first-episode-psychosis-patients-a-7-month-follow-up-study
#1
Roman Balõtšev, Liina Haring, Kati Koido, Vambola Leping, Kärt Kriisa, Mihkel Zilmer, Veiko Vasar, Anneli Piir, Aavo Lang, Eero Vasar
AIM: Second-generation antipsychotics are commonly used to treat schizophrenia, but may cause metabolic syndrome (MetS) in a subset of patients. The mechanisms of antipsychotic-related metabolic changes remain to be established, especially in first-episode psychosis (FEP) patients. METHODS: In the present study, we used a chip technology to measure metabolic (C-peptide, insulin, leptin, adiponectin and resistin) and inflammatory biomarkers (ferritin, interleukin-6, interleukin-1α, tumour necrosis factor-α and plasminogen activator inhibitor-1) in the serum samples of a population of FEP patients before and after 7 months of antipsychotic drug treatment, compared to control subjects (CS)...
July 18, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28718688/effect-of-adjunctive-ranitidine-for-antipsychotic-induced-weight-gain-a-systematic-review-of-randomized-placebo-controlled-trials
#2
Xiao-Jing Gu, Rui Chen, Chen-Hui Sun, Wei Zheng, Xin-Hu Yang, Shi-Bin Wang, Gabor S Ungvari, Chee H Ng, Andrei Golenkov, Grace K I Lok, Lu Li, Ines H I Chow, Fei Wang, Yu-Tao Xiang
This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. Case reports/series, non-randomized or observational studies, reviews, and meta-analyses were excluded. The primary outcome measures were body mass index (BMI) (kg/m(2)) and body weight (kg). Four RCTs with five study arms were identified and analyzed...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28688350/changes-in-the-cytokine-profile-in-first-episode-drug-na%C3%A3-ve-patients-with-psychosis-after-short-term-antipsychotic-treatment
#3
Petros Petrikis, Paraskevi V Voulgari, Alexandros T Tzallas, Vassiliki A Boumba, Dimitra T Archimandriti, Dimitrios Zambetas, Ioannis Papadopoulos, Ioannis Tsoulos, Petros Skapinakis, Venetsanos Mavreas
An increasing body of evidence suggests that antipsychotic medication can cause immunological changes that could be attributed to the amelioration of psychotic symptoms or the metabolic side effects of the drugs. So far, the results of the studies remain controversial. Our aim was to compare the levels of interleukin (IL) IL-2, IL-6 and transforming growth factor-β2 (TGF-β2) in drug-naïve, first-episode patients with psychosis before and after six weeks of antipsychotic medication. Thirty-nine first-episode patients with psychosis were enrolled in the study...
July 3, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28672735/safety-concerns-associated-with-second-generation-antipsychotic-long-acting-injection-treatment-a-systematic-update
#4
Salvatore Gentile
Background It has been recently suggested that second-generation antipsychotic long-acting injection (SGA-LAIs) are underutilized in clinical practice, despite that their costs significantly impact on national health system budgets. Hence, an updated analysis of safety data shown by SGA-LAIs may contribute to clarify their role in clinical practice. Materials and methods English-language, peer-reviewed articles reporting updated, primary findings on the SGA-LAI safety were identified (updated through an electronic search of five databases - PubMed, EMBASE, PsycInfo, DARE and the Cochrane Library)...
June 23, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28668717/predictors-of-rapid-high-weight-gain-in-schizophrenia-longitudinal-analysis-of-the-french-face-sz-cohort
#5
O Godin, M Leboyer, F Schürhoff, L Boyer, M Andrianarisoa, L Brunel, E Bulzacka, B Aouizerate, F Berna, D Capdevielle, T D'Amato, H Denizot, C Dubertret, J Dubreucq, C Faget, F Gabayet, P M Llorca, J Mallet, D Misdrahi, C Passerieux, R Rey, R Richieri, A Schandrin, M Urbach, P Vidailhet, D Costagliola, G Fond
Metabolic syndrome (MetS) is highly prevalent in schizophrenia. However very little is known about the time course of MetS and its components. The few longitudinal studies that have been carried out had small sample sizes and a short follow-up. The aim of our study was to evaluate the prevalence of MetS and its components, at baseline and one year later, and to investigate predictors of weight gain (WG) in a cohort of individuals with schizophrenia. We followed 167 schizophrenia patients from the FACE-SZ cohort for one year...
June 20, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28663026/evolution-of-metabolic-risk-factors-over-a-two-year-period-in-a-cohort-of-first-episodes-of-psychosis
#6
Miquel Bioque, M A Paz García-Portilla, Clemente García-Rizo, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Julio Bobes, Miguel Gutiérrez-Fraile, Roberto Rodriguez-Jimenez, Gisela Mezquida, Adrián Llerena, Jeronimo Saiz-Ruiz, Miguel Bernardo
Patients with a first episode of psychosis (FEP) display a broad range of metabolic risk factors related to the development of diverse medical comorbidities. Initial stages of these disorders are essential in understanding the increased vulnerability of developing cardiometabolic disturbances, associated with a reduced life expectancy. This study aimed to evaluate the metabolic profile of a cohort of patients with a FEP and its evolution during a two year follow-up, as well as the factors that influence the changes in their metabolic status...
June 26, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28626268/sex-differences-in-antipsychotic-related-metabolic-functioning-in-schizophrenia-spectrum-disorders
#7
A Zarina Kraal, Kristen M Ward, Vicki L Ellingrod
The adverse metabolic risks associated with second generation antipsychotics (SGAs) are well known, and likely contribute to the high rate of premature mortality due to cardiovascular disease in schizophrenia. Female schizophrenia patients appear to be diagnosed with metabolic diseases at higher rates than males, which may reflect disparate adverse responses to SGAs. However, the relationship between sex, metabolic risk, and drug use is less developed. We aimed to explore this relationship further by identifying rates of metabolic disease in community dwelling schizophrenia patients by sex and SGA risk...
May 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28599949/quetiapine-extended-release-versus-aripiprazole-in-children-and-adolescents-with-first-episode-psychosis-the-multicentre-double-blind-randomised-tolerability-and-efficacy-of-antipsychotics-tea-trial
#8
Anne Katrine Pagsberg, Pia Jeppesen, Dea Gowers Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Peter Jantzen, Simone Rasmussen, Eva Ann-Sofie Saldeen, Maj-Britt Glenn Lauritsen, Niels Bilenberg, Anne Dorte Stenstrøm, Louise Nyvang, Sarah Madsen, Thomas M Werge, Theis Lange, Christian Gluud, Maria Skoog, Per Winkel, Jens Richardt M Jepsen, Birgitte Fagerlund, Christoph U Correll, Anders Fink-Jensen
BACKGROUND: Head-to-head trials to guide antipsychotic treatment choices for paediatric psychosis are urgently needed because extrapolations from adult studies might not be implementable. In this superiority trial with two-sided significance testing, we aimed to compare the efficacy and safety of quetiapine-extended release (quetiapine-ER) versus aripiprazole in children and adolescents with first-episode psychosis, to determine whether differences between the two treatments were sufficient to guide clinicians in their choice of one drug over the other...
June 6, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28595931/aripiprazole-induced-adverse-metabolic-alterations-in-polyi-c-neurodevelopmental-model-of-schizophrenia-in-rats
#9
Katerina Horska, Jana Ruda-Kucerova, Eva Drazanova, Michal Karpisek, Regina Demlova, Tomas Kasparek, Hana Kotolova
Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis...
September 1, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28586744/protective-effects-of-green-tea-on-olanzapine-induced-metabolic-syndrome-in-rats
#10
Bibi Marjan Razavi, Fariba Lookian, Hossein Hosseinzadeh
Atypical antipsychotics particularly olanzapine are associated with obesity and serious metabolic disturbances. As green tea (Camellia sinensis) is generally associated with beneficial effects on obesity and other metabolic disturbances, this study was undertaken to evaluate the effect of green tea aqueous extract (GTAE) on olanzapine induced weight gain and metabolic abnormalities in rats. Male Wistar rats were divided into eight groups: control, olanzapine (5mg/kg/day, IP.), GTAE (25, 50 and 100mg/kg/day, IP...
August 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28585153/second-generation-antipsychotics-and-metabolic-side-effects-a-systematic-review-of-population-based-studies
#11
REVIEW
Lauren Hirsch, Jaeun Yang, Lauren Bresee, Nathalie Jette, Scott Patten, Tamara Pringsheim
INTRODUCTION: There is strong evidence from randomized controlled trials (RCTs) that second-generation antipsychotic (SGA) medications are associated with metabolic adverse events. However, with the recent increases in the use of SGAs worldwide and frequent off-label use, it is unclear whether these associations are generalizable to populations beyond those included in RCTs. OBJECTIVES: This review aims to characterize the impact of SGAs on the population through a systematic review of population-based studies of SGA users...
June 5, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/28584269/time-dependent-changes-and-potential-mechanisms-of-glucose-lipid-metabolic-disorders-associated-with-chronic-clozapine-or-olanzapine-treatment-in-rats
#12
Xuemei Liu, Zhixiang Wu, Jiamei Lian, Chang-Hua Hu, Xu-Feng Huang, Chao Deng
Chronic treatment with second-generation antipsychotic drugs (SGAs) has been associated with an increased risk of metabolic syndrome. To evaluate the longitudinal changes in glucose-lipid homeostasis after SGA use, we studied the time-dependent effects of olanzapine (OLZ) (3 mg/kg, b.i.d.) or clozapine (CLZ) (20 mg/kg, b.i.d.) treatment on metabolic profiles for 9 weeks in rats. Although only OLZ significantly increased body weight in rats, both OLZ and CLZ elevated blood lipid levels. Chronic OLZ treatment induced significant weight gain leading to a higher fasting insulin level and impaired glucose tolerance, whereas CLZ lowered fasting insulin levels and impaired glucose tolerance independent of weight gain...
June 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28557969/-metabolic-safety-of-antidepressant-medicines
#13
Wojciech Łężak, Łukasz Mokros, Michał Seweryn Karbownik, Andrzej Witusik, Marcin Kosmalski, Edward Kowalczyk, Tadeusz Pietras
Metabolic syndrome is a very serious health issue, not only from internal medicine's point of view. Patients suffering from overweight, arterial hypertension, lipids and carbohydrates metabolism disorders are also in the circle of interest of other areas of medicine, including psychiatry. Currently, one of key problems of pharmacotherapy is a comorbidity of metabolic syndrome and mental disorder. Depression is more common than schizophrenia. Despite the fact that in everyday clinical practice there are more patients with depression than schizophrenia, there is a bigger interest among scientists for metabolic syndrome after antipsychotic drugs than as an effect of use of antidepressant agents...
May 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28507773/rapid-onset-clozapine-induced-loss-of-glycaemic-control-case-report
#14
Alejandro Porras-Segovia, Amir Krivoy, Mark Horowitz, George Thomas, Mark Bolstridge, Dragos Ion, Sukhwinder S Shergill
Clozapine has proved to be an effective antipsychotic for the treatment of refractory schizophrenia - characterised by the persistence of symptoms despite optimal treatment trials with at least two different antipsychotics at adequate dose and duration - but its use is hampered by adverse effects. The development of clozapine-induced diabetes is commonly considered to arise as part of a metabolic syndrome, associated with weight gain, and thus evolves slowly. We present the case of an individual with refractory schizophrenia and metformin-controlled diabetes who developed rapid-onset insulin-dependent hyperglycaemia immediately after starting clozapine...
May 2017: BJPsych Open
https://www.readbyqxmd.com/read/28492956/relationship-between-the-rs1414334-c-g-polymorphism-in-the-htr2c-gene-and-smoking-in-patients-treated-with-atypical-antipsychotics
#15
José María Rico-Gomis, Antonio Palazón-Bru, Irene Triano-García, Luis Fabián Mahecha-García, Ana García-Monsalve, Andrés Navarro-Ruiz, Berta Villagordo-Peñalver, Alicia Martínez-Hortelano, Vicente Francisco Gil-Guillén
An association has been found between the C allele of the rs1414334 polymorphism in the HTR2C gene and the metabolic syndrome in psychiatric patients. However, no study has yet evaluated whether this allele is associated with smoking. To assess this issue, therefore, we performed a cross-sectional study with a sample of 166 adult patients treated with atypical antipsychotics in 2012-2013 in a region of Spain. The primary variable was the presence of the C allele of the rs1414334 polymorphism in the HTR2C gene...
April 12, 2017: Adicciones
https://www.readbyqxmd.com/read/28464773/the-role-of-atypical-antipsychotics-in-sexuality-road-to-recovery-in-schizophrenia
#16
Raja Lope Adam, Hatta Sidi, Marhani Midin, Hazli Zakaria, Srijit Das, Khairi Che Mat
Sexuality is an important dimension in human beings as a form of expression of individuality. For many decades, sexual functioning has been a neglected area among patients suffering from schizophrenia. It was a presumption that patients with schizophrenia could be asexual and this could be secondary to overwhelming situations of delusion, hallucination, hostility and negative symptoms among others. The deficient in sexual functioning are due to innate factors, i.e. negative symptoms (apathy, avolition and amotivation) and also as a result of prefrontal dysfunction, i...
May 2, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28454923/prevalence-and-predictors-of-metabolic-syndrome-in-patients-with-schizophrenia-and-healthy-controls-a-study-in-rural-south-indian-population
#17
Vikram Singh Rawat, Suhas Ganesh, Somashekar Bijjal, K Shanivaram Reddy, Vikas Agarwal, Renuka Devi, Chennaveerachari Naveen Kumar, Rita Christopher, Jagadisha Thirthalli
INTRODUCTION: Metabolic syndrome (MetS) has been extensively studied as a co-morbidity in patients with schizophrenia. A disparity is noted between hospital and community based estimates in India. We aimed to examine the prevalence and predictors of MetS in schizophrenia patients and general population controls in a rural population in South India. METHODS: Patients (n=157) and general population controls (n=263) were recruited from a rural area in South India. Diagnosis of MetS was established using International Diabetes Federation (IDF) criteria...
April 25, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28449563/relationship-between-serum-bilirubin-levels-and-metabolic-syndrome-in-patients-with-schizophrenia-spectrum-disorders
#18
Filiz Karadag, Ceyhan Balci Sengul, Yasar Enli, Kamuran Karakulah, Huseyin Alacam, Bunyamin Kaptanoglu, Ozgur Kalkanci, Hasan Herken
Objective: We investigated the relationship between serum bilirubin levels and metabolic syndrome (MetS), and the longitudinal effects of baseline serum bilirubin concentrations on MetS in patients with schizophrenia spectrum disorders undergoing atypical antipsychotics. Methods: The sample of this study consisted of 131 patients with schizophrenia spectrum disorders. Waist circumference, blood pressure, and levels of triglycerides, high-density lipoprotein cholesterol, fasting glucose, and insulin were evaluated at baseline and at month six...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28449562/longer-telomere-length-of-t-lymphocytes-in-patients-with-early-and-chronic-psychosis
#19
Yin Cui, Vishwanath Vasudev Prabhu, Thong Ba Nguyen, Subramaniam Mohana Devi, Young-Chul Chung
Objective: To investigate pathological conditions that act as sources of pro-inflammatory cytokines and cytotoxic substances to examine telomere length (TL) in patients with either early (duration of illness [DI] ≤5 years) or chronic (DI >5 years) psychosis using T lymphocytes. Methods: Based on these factors and the important role that T lymphocytes play in inflammation, the present study measured the TL of T lymphocytes in patients with either early or chronic psychosis...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28443526/transformation-of-excess-mortality-in-people-with-schizophrenia-and-bipolar-disorder-in-taiwan
#20
Y-J Pan, L-L Yeh, H-Y Chan, C-K Chang
BACKGROUND: Given the concerns regarding the adverse health outcomes associated with weight gain and metabolic syndrome in relation to use of second-generation antipsychotics (SGAs), we aimed in this study to explore whether the increase in the use of SGAs would have any impacts on the trend of excess mortality in people with schizophrenia and bipolar disorder (BPD). METHOD: Two nationwide samples of individuals with schizophrenia and BPD were identified in Taiwan's National Health Insurance Research Database in 2003 and in 2008, respectively...
April 26, 2017: Psychological Medicine
keyword
keyword
73394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"